Use of terbinafine in rare and refractory mycoses

Future Microbiology

Volumn 3, Issue 1, 2008, Pages 9-17

  Revankar, Sanjay G ^a   Nailor, Michael D ^b   Sobel, Jack D ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Aspergillosis; Azole resistance; Candida; Itraconazole; Terbinafine

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GAMMA GLUTAMYLTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; POSACONAZOLE; PYRROLE DERIVATIVE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TERBINAFINE; TRIAZOLE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VORICONAZOLE; WARFARIN; NAPHTHALENE DERIVATIVE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BONE MARROW TOXICITY; CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CRYPTOCOCCOSIS; DERMATOMYCOSIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVIDENCE BASED MEDICINE; FLATULENCE; FUNGEMIA; HUMAN; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MALAISE; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; ONYCHOMYCOSIS; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STEVENS JOHNSON SYNDROME; TASTE DISORDER; TINEA PEDIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VISUAL DISORDER; ANIMAL; ANTIFUNGAL RESISTANCE; CANDIDA; DRUG EFFECT; MICROBIOLOGY; TREATMENT OUTCOME;

CANDIDA; TINEA PEDIS;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; DERMATOMYCOSES; DRUG RESISTANCE, FUNGAL; HUMANS; MYCOSES; NAPHTHALENES; TREATMENT OUTCOME; TRIAZOLES;

EID: 39049158776     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.1.9     Document Type: Review

References (73)

1. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH: Amphotericin B: time for a new gold standard. Clin. Infect. Dis. 37(3), 415-425 (2003).
2. Johnson LB, Kauffman CA: Voriconozole: a new triazole antifungal agent. Clin. Infect. Dis. 36(5), 630-637 (2003).
3. Herbrecht R: Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58, 612 (2004).
4. Cappelletty D, Eiseistein-McKitrick K: The echinocandins. Pharmacotherapy 27(3), 369-388 (2007).
5. Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V: The lipid formulations of amphotericin B. Eypert Opin. Pharmacother. 4(8), 1277-1287 (2003).
6. Vermes A, Guchelaar HJ, Dankert J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimcrob. Chemother. 46, 171-179 (2000).
7. Cribier BJ, Bakshi R: Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br. J. Dermatol. 150(3), 414-420 (2004).
8. Humphreys F: Terbinafine. J. Drug Evaluation 2(5), 133-155 (2004).
9. Ryder NS: Terbinafine: mode of action and properties of squalene epoxidase inhibition. Br. J. Dermatol. 126(Suppl. 39), 2-7 (1992).
10. Jessup CJ, Ryder NS, Ghannoum MA: An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38(2), 155-159 (2000).
11. Dannaoui E, Meletiadis J, Tortorano AM et al.: Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. J. Med. Microbiol. 53(Pt 2), 129-134 (2004).
12. Kantarcioglu AS, Yucel A: In vitro activities of terbinafine, itraconazole and amphotericin B against Aspergillus and Cladosporium species. J. Chemother. 14(6), 562-567 (2002).
13. Ryder NS, Leitner I: Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med. Mycol. 39(1), 91-95 (2001).
14. Karaaslan A, Arikan S, Ozcan M, Ozcan KM: In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosiss. Mycoses 47(7), 284-287 (2004).
15. McGinnis MR, Pasarell L: In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med. Mycol. 36(4), 243-246 (1998).
16. Meletiadis J, Meis JF, de Hoog GS, Verweij PE: In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs. Mycoses 13(7-8), 309-312 (2000).
17. Vitale RG, De Hoog GS, Verweij PE: In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against Exophiala sphinifera and evaluation of post-antifungal effects. Med. Mycol. 41(4), 301 (2003).
18. Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J: In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn. Microbiol. Infect. Dis. 48(1), 69-71 (2004).
19. Gilgado F, Serena C, Cano J, Gene J, Guarro J: Antifungal susceptibilities of the species of the Pseudallescehria bordii complex. Antimicrob. Agents Chemother. 50(12), 4211-4213 (2006).
20. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE: In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 44(2), 470-472 (2000).
21. Meletiadis J, Mouton JW, Meis JF, Verweij PE: In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47(1), 106-117 (2003).
22. Sorensen KN, Sobel RA, Clemons KV et al.: Comparative efficacies of terbinafine and fluconazole in treatment of experimental coccidioidal meningitis in a rabbit model. Antimicrob. Agents Chemother. 44(11), 3087-3091 (2000).
23. Kirkpatrick WR, Vallor AC, McAtee RK et al.: Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Antimicrob. Agents Chemother. 49(11), 4751-4753 (2005).
24. Schmitt HJ, Andrade J, Edwards F, Niki Y, Bernard E, Armstrong D: Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur. J. Clin. Microbiol. Infect. Dis. 9(11), 832-835 (1990).
25. Dannaoui E, Mouton JW, Meis JF, Verweij PE: Efficacy of antifungal therapy in a nonneutropenic routine model of zygomycosis. Antimicrob. Agents Chemother. 46(6), 1953-1959 (2002).
26. Finlay AY: Global overview of Lamisil. Br. J. Dermatol. 130(Suppl. 43), 1-3 (1994).
27. Roberts DT: Oral therapeutic agents in fungal nail disease. J. Am. Acad. Dermatol. 31(3 Pt 2), S78-S81 (1994).
28. Nedelman JR, Giviansky E, Robbins BA: Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. J. Clin. Pharmacol. 36(5), 452-461 (1996).
29. Lamisil, Package insert. Novartis Pharmaceuticals, Basel, Switzerland.
30. Kovarik JM, Kirkesseli S, Humbert H, Grass P, Kutz K: Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in health volunteers. Br. J. Dermatol. 126(Suppl. 39), 8-13 (1992).
31. Schiraldi G, Della Patrona S, Colombo MD et al.: Plasma and lung concentration of terbinafine: a pilot study. G. Ital. Tuberc. Mal. Torace 60(4), 235-240 (2006).
32. Gupta AK, Ryder JE, Johnson AM: Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br. J. Dermatol. 150(3), 537-544 (2004).
33. Koumantaki E, Kakourou T, Rallis E, Riga P, Georgalla S: Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr. Dermatol. 18(4), 339-342 (2001).
34. Hamm H, Schwinn A, Brautigam M, Weidinger G: Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. The Study Group. Br. J. Dermatol. 140(3), 480-482 (1999).
35. Schiraldi GF, Gramegna G, De Rosa C et al.: Chronic pulmonary aspergillosis: current classification and therapy. Curr. Opin. Investig. Drugs 4(2), 186-191 (2003).
36. Schiraldi GF, Colombo MD, Harari S et al.: Terbinafine in the treatment of non-immunocompromised compassionate cases of bronchopulmonary aspergillosis. Mycoses 39(1-2), 5-12 (1996).
37. Schiraldi GF, Cicero SL, Colombo MD, Rossato D, Ferrarese M, Soresi E: Refractory pulmonary aspergillosis: compassionate trial with terbinafine. Br. J. Dermatol. 134(Suppl. 46), 25-29 (1996).
38. Harari S, Schiraldi G, de Juli E, Gronda E: Relapsing Aspergillus bronchitis in a double lung transplant patient, successfully treated with a new oral antimycotic agent. Chest 111(3), 835-836 (1997).
39. Rotoli M, Sascaro G, Cavalieri S: Aspergillus versicolor infection of the external auditory canal successfully treated with terbinafine. Dermatology 202(2), 143 (2001).
40. Esterre P, Inzan CK, Ramarcel ER et al.: Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br. J. Dermatol. 134 (Suppl. 46), 33-36 (1996).
41. Gupta AK, Taborda PR, Sanzovo AD: Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by F onsecaea pedrosoi in Brazil. Med. Mycol. 40, 529-534 (2002).
42. Xibao Z, Changxing L, Quan L, Yuqing H: Treatment of chromoblastomycosis with terbinafine: a report of four cases. J. Dermatol. Treat. 16(2), 121-124 (2005).
43. Tanuma H, Hiramatsu M, Mukai H et al.: Case report. A case of chromoblastomycosis effectively treated with terbinafine. Characteristics of chromoblastomycosis in the Kitasato region, Japan. Mycoses 43(1-2), 79-83 (2000).
44. Ezzine-Sebai N, Benmously R, Fazaa B, Chaker E, Zermani R, Kamoun MR: Chromomyeosis arising in a Tunisian man. Dermatol. Online J. 11(2), 14 (2005).
45. Sevigny GM, Ramos-Caro FA: Treatment of chromoblastomycosis due to Fonsecaea pedrosoi with low-dose terbinafine. Cutis 66(1), 45-46 (2000).
46. Brown M, Pasvol G: Images in clinical medicine. Chromoblastomycosis. N. Engl. J. Med. 352(20), E19 (2005).
47. Bonifaz A, Carrasco-Gerard E, Saul A: Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44, 1-7 (2001).
48. Rallis E, Frangoulis E: Successful treatment of subcutaneous phaeohyphomycosis owing to Exophiala jeanselmei with oral terbinafine. Int. J. Dermatol. 45(11), 1369-1370 (2006).
49. Agger WA, Andes D, Burgess JW: Exophiala jeanselmei infection in a heart transplant recipient successfully treated with oral terbinafine. Clin. Infect. Dis. 38(11), e112 (2004).
50. Anderson KL, Mitra S, Salouti R, Pham TA, Taylor HR: Fungal keratitis caused by Paecilomyces Iilacinus associated with a retained intracorneal hair. Cornea 23(5), 516 (2004).
51. Clark NM: Paecilomyces Iilacinus infection in a heart transplant recipient and successful treatment with terbinafine. Clin. Infect. Dis. 28(5), 1169-1170 (1999).
52. Mursch K, Trnovec S, Ratz H et al.: Successful treatment of multiple Pseudallescheria boydii brain abscesses and ventriculitis/ependymitis in a 2-year-old child after a near-drowning episode. Childs Nerv. Syst. 22(2), 189-192 (2006).
53. Verweij PE, Cox NJ, Meis JF: Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur. J. Clin. Microbiol. Infect. Dis. 16(1), 26-28 (1997).
54. Whyte M, Irving H, O'Regan P, Nissen M, Siebert D, Labrom R: Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr. Infect. Dis. J. 24(4), 375-377 (2005).
55. Howden BP, Slavin MA, Schwarer AP, Mijch AM: Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. 22(2), 111-113 (2003).
56. Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC: Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole, plus terbinafine, without the need for radical surgery. Mycoses 46(5-6), 233-236 (2003).
57. Sellier P, Monsuez JJ, Lacroix C et al.: Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient. Clin. Infect. Dis. 30(5), 820-823 (2000).
58. Bruynzeel I, Starink TM: Granulomatous skin infection caused by Scapulariopsis brevicaulis. J. Am. Acad. Dermatol. 39(2 Pt 2), 365-367 (1998).
59. Chapman SW, Pappas P, Kauffmann C et al.: Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day[-1]) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47(1-2), 62-68 (2004).
60. Vieira MR, Milheiro A, Pacheco FA: Phaeohyphomycosis due to Cladasporium cladosporioides. Med. Mycol. 39(1), 135 (2001).
61. Rothe A, Seibold M, Hoppe T et al.: Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann. Hematol. 83(6), 394-397 (2004).
62. N'Diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R: Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int. J. Dermatol. 45(2), 154-157 (2006).
63. Destino L, Sutton DA, Helon AL et al.: Severe osteomyelitis caused by Mycellophthora thermophila after a pitchfork injury. Ann. Clin. Microbiol. Antimicrob. 5, 21 (2006).
64. Wong PK, Ching WT, Kwon-Chung KJ, Meyer RD: Disseminated Phialophora parasitica infection in humans: case report and review. Rev. Infect. Dis. 11(5), 770-775 (1989).
65. Shenep JL, English BK, Kaufman L et al.: Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin. Infect. Dis. 27(6), 1388-1393 (1998).
66. Ajit C, Suvannasankha A, Zaeri N, Munoz SJ: Terbinafine-associated hepatotoxicity. Am. J. Med. Sci. 325(5), 292-295 (2003).
67. Terbinafine: serious adverse effects including Stevens-Johnson syndrome. WHO Pharmaceuticals Newsletter 6(5), 5 (2006).
68. Zapata Garrido AJ, Romo AC, Padilla FB: Terbinafine hepatotoxicity. A case report and review of literature. Ann. Hepatol. 2(1), 47-51 (2003).
69. Perveze Z, Johnson MW, Rubin RA et al.: Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 13(1), 162-164 (2007).
70. O'Sullivan DP, Needham CA, Bangs A, Atkin K, Kendall FD: Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. Br. J. Clin. Pharmacol. 42(5), 559-565 (1996).
71. Duxbury AJ, Oliver RJ, Pemberton MN: Persistent impairment of taste associated with terbinafine. Br. Dent. J. 188(6). 295-296 (2000).
72. Lemont H, Sabo M: Terbinafine-associated taste disturbance with normal taste threshold scores. J. Am. Podiatr. Med. Assoc. 91(10), 540-541 (2001).
73. Ching CH, Young-Xu Y, Kurth T, Orav JE, Chan AK: The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am. J. Med. 120(9), 791-798 (2007).